Endo Pharmaceuticals Holdings Inc (ENDP) 70.61 $ENDP
Endo Announces Appearances at Upcoming Conferences
PR Newswire Europe - Fri May 09, 8:01AM CDT
Endo International plc announced today that Rajiv De Silva, President and CEO, will present a corporate overview at the 2014 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 13, 2014 at 1:00 p.m. Eastern Time and at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 9:00 a.m. Eastern Time.
Earnings Releases, Dividends Announcements, and Product Improvements - Analyst Notes on Express Scripts, Humana, Endo, Incyte and Citrix
PR Newswire - Thu May 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Express Scripts Holding Company (NASDAQ: ESRX), Humana Inc. (NYSE: HUM), Endo International Plc (NASDAQ: ENDP), Incyte Corporation (NASDAQ: INCY) and Citrix Systems, Inc. (NASDAQ: CTXS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2197-100free.
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
Endo Health Solutions Inc. Final Results and Settlement of Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Tue May 06, 4:46PM CDT
Endo International plc ("Endo" or the "Company"
announced today the final results and settlement of its wholly-owned subsidiary Endo Health Solutions Inc.'s ("EHSI" previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes" , 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7 1/4% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019 (the "2019 New Endo Finance Notes" , 7.00% Senior Notes due 2020 (the "2020 New Endo Finance Notes" and 7.25% Senior Notes due 2022 (the "2022 New Endo Finance Notes" and together with the 2019 New Endo Finance Notes and the 2020 New Endo Finance Notes, the "New Endo Finance Notes" , respectively, issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that, among other things, (i) deleted in their entirety substantially all the restrictive covenants in each indenture, (ii) modified the covenants regarding mergers and consolidations, and (iii) eliminated certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange" .
Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter.
Endo International plc (ENDP) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:21AM CDT
Endo International plc (ENDP) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Technical Data on Top Gainers -- Research on Yelp, Endo Intl., Weight Watchers Intl., and Burlington Stores
PR Newswire - Fri May 02, 7:00AM CDT
The US markets saw a mixed sentiment on Thursday, May 01, 2014, with the NASDAQ Composite closing at 4,127.45, up 0.31%, the Dow Jones Industrial Average ending the session 0.13% lower at 16,558.87, and the S&P 500 edging 0.01% lower to finish the trading session at 1,883.68. During the session gains in the Consumer Discretionary, Telecommunication Services and Utilities sectors positively impacted the broader market, while some retraction came in from Materials, Energy, and Industrials sectors. A number of stocks saw large movements, including Yelp Inc. (NYSE: YELP), Endo International PLC (NASDAQ: ENDP), Weight Watchers International Inc. (NYSE: WTW) and Burlington Stores Inc. (NYSE: BURL). Free technical research on YELP, ENDP, WTW and BURL can be downloaded upon signing up at:
Endo profit tops despite charge
at Investor's Business Daily - Thu May 01, 5:51PM CDT
Endo Int'l (ENDP) shares rose 5.4% to 66.36 after the drugmaker said EPS fell 16% to 92 cents, beating Q1 estimates by 8 cents. That excluded a $625 mil charge to boost liability reserves to cover settlements resolving 20,000 claims over its vaginal...
Levin Simes LLP Settles AMS Transvaginal Mesh Cases
Marketwire - Thu May 01, 3:47PM CDT
Levin Simes LLP announced that an agreement in principle has been reached to settle approximately 20,000 claims related to vaginal mesh products sold by American Medical Systems, Inc. (AMS), a subsidiary of Endo Pharmaceuticals. These include claims of women represented by Levin Simes and several other law firms. Endo Pharmaceuticals will pay approximately $830 million for resolution of those claims.
Endo Reports First Quarter Financial Results
PR Newswire Europe - Thu May 01, 6:25AM CDT
Total quarterly revenues of $595 million, reported diluted (GAAP) loss per share of $3.41 and adjusted diluted EPS of $0.92. -- Company raises expected 2014 revenues to a range from $2.55 billion to $2.64 billion and raises expected 2014 adjusted diluted EPS to a range from $3.60 to $3.85. -- Company expects 2014 reported diluted (GAAP) loss per share to be in the range from $1.35 to $1.10. -- Company announced the acquisitions of Grupo Farmaceutico Somar and Sumavel DosePro as it continues to transform into a leading global specialty healthcare company. -- Company entered into agreements to repurchase approximately $240 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2015. -- Company Reaches Agreements in Principle to Settle a Substantial Majority of AMS Litigation Cases.
Financial Release Dates -- Research on T-MobileUS, Endo Intl., Xcel Energy, and North American Palladium
PR Newswire - Thu May 01, 3:03AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: T-Mobile US Inc. (NYSE: TMUS), Endo International PLC (NASDAQ: ENDP), Xcel Energy Inc. (NYSE: XEL) and North American Palladium Ltd (NYSE MKT: PAL). Full earnings notes on TMUS, ENDP, XEL and PAL can be downloaded upon signing up at:
Stock Price Updates, Recognitions, Earnings Releases, and Acquisitions of Rights - Analyst Notes on HCA, Express Scripts, Tenet, Quest Diagnostics and Endo
PR Newswire - Thu May 01, 2:53AM CDT
Today, Analysts Review released its analysts' notes regarding HCA Holdings, Inc. (NYSE: HCA), Express Scripts Inc. (NASDAQ: ESRX), Tenet Healthcare Corp. (NYSE: THC), Quest Diagnostics Inc. (NYSE: DGX) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1814-100free.
Endo Health Solutions Inc. Announces Extension of Expiration Date and Reopening of Withdrawal Rights in Exchange Offers for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Wed Apr 30, 5:44PM CDT
Endo International plc ("Endo" or the "Company" announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has further extended the expiration date and reopened withdrawal rights in its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014, as supplemented from time to time.
Endo Reaches Agreements in Principle to Settle a Substantial Majority of AMS Litigation Cases
PR Newswire Europe - Wed Apr 30, 3:38PM CDT
Endo International plc today announced that it has reached agreements in principle with several leading plaintiffs' law firms, including Motley Rice LLC, Blasingame, Burch, Garrard & Ashley, P.C., Levin Simes LLP, and Clark, Love & Hutson, G.P., to resolve approximately 20,000 claims relating to vaginal mesh products sold by Endo's AMS subsidiary. The agreements, which are subject to final documentation, were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault. The settlements, once final, will resolve a substantial majority of the AMS vaginal mesh-related claims.
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
Endo Announces Appearances at Upcoming Conferences
PR Newswire Europe - Fri May 09, 8:01AM CDT
Endo International plc announced today that Rajiv De Silva, President and CEO, will present a corporate overview at the 2014 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 13, 2014 at 1:00 p.m. Eastern Time and at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 9:00 a.m. Eastern Time.
Earnings Releases, Dividends Announcements, and Product Improvements - Analyst Notes on Express Scripts, Humana, Endo, Incyte and Citrix
PR Newswire - Thu May 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Express Scripts Holding Company (NASDAQ: ESRX), Humana Inc. (NYSE: HUM), Endo International Plc (NASDAQ: ENDP), Incyte Corporation (NASDAQ: INCY) and Citrix Systems, Inc. (NASDAQ: CTXS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2197-100free.
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
Endo Health Solutions Inc. Final Results and Settlement of Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Tue May 06, 4:46PM CDT
Endo International plc ("Endo" or the "Company"
announced today the final results and settlement of its wholly-owned subsidiary Endo Health Solutions Inc.'s ("EHSI" previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019 (the "2019 Existing EHSI Notes" , 7.00% Senior Notes due 2020 (the "2020 Existing EHSI Notes" and 7 1/4% Senior Notes due 2022 issued by EHSI (the "2022 Existing EHSI Notes" and, together with the 2019 Existing EHSI Notes and the 2020 Existing EHSI Notes, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019 (the "2019 New Endo Finance Notes" , 7.00% Senior Notes due 2020 (the "2020 New Endo Finance Notes" and 7.25% Senior Notes due 2022 (the "2022 New Endo Finance Notes" and together with the 2019 New Endo Finance Notes and the 2020 New Endo Finance Notes, the "New Endo Finance Notes" , respectively, issued by Endo Finance LLC and Endo Finco Inc. and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries, and the related solicitation of consents to amend the Existing EHSI Notes and the indentures governing the Existing EHSI Notes. Consents were solicited in respect of the indentures governing each series of the Existing EHSI Notes to approve proposed amendments that, among other things, (i) deleted in their entirety substantially all the restrictive covenants in each indenture, (ii) modified the covenants regarding mergers and consolidations, and (iii) eliminated certain events of default. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014 (as amended from time to time, the "Offer to Exchange" . Earnings Beat at Endo, Shares Up on Improved Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 11:10AM CDT
Endo (ENDP) beat on earnings in the first quarter.
Endo International plc (ENDP) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:21AM CDT
Endo International plc (ENDP) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Technical Data on Top Gainers -- Research on Yelp, Endo Intl., Weight Watchers Intl., and Burlington Stores
PR Newswire - Fri May 02, 7:00AM CDT
The US markets saw a mixed sentiment on Thursday, May 01, 2014, with the NASDAQ Composite closing at 4,127.45, up 0.31%, the Dow Jones Industrial Average ending the session 0.13% lower at 16,558.87, and the S&P 500 edging 0.01% lower to finish the trading session at 1,883.68. During the session gains in the Consumer Discretionary, Telecommunication Services and Utilities sectors positively impacted the broader market, while some retraction came in from Materials, Energy, and Industrials sectors. A number of stocks saw large movements, including Yelp Inc. (NYSE: YELP), Endo International PLC (NASDAQ: ENDP), Weight Watchers International Inc. (NYSE: WTW) and Burlington Stores Inc. (NYSE: BURL). Free technical research on YELP, ENDP, WTW and BURL can be downloaded upon signing up at:
Endo profit tops despite charge
at Investor's Business Daily - Thu May 01, 5:51PM CDT
Endo Int'l (ENDP) shares rose 5.4% to 66.36 after the drugmaker said EPS fell 16% to 92 cents, beating Q1 estimates by 8 cents. That excluded a $625 mil charge to boost liability reserves to cover settlements resolving 20,000 claims over its vaginal...
Levin Simes LLP Settles AMS Transvaginal Mesh Cases
Marketwire - Thu May 01, 3:47PM CDT
Levin Simes LLP announced that an agreement in principle has been reached to settle approximately 20,000 claims related to vaginal mesh products sold by American Medical Systems, Inc. (AMS), a subsidiary of Endo Pharmaceuticals. These include claims of women represented by Levin Simes and several other law firms. Endo Pharmaceuticals will pay approximately $830 million for resolution of those claims.
Endo Reports First Quarter Financial Results
PR Newswire Europe - Thu May 01, 6:25AM CDT
Total quarterly revenues of $595 million, reported diluted (GAAP) loss per share of $3.41 and adjusted diluted EPS of $0.92. -- Company raises expected 2014 revenues to a range from $2.55 billion to $2.64 billion and raises expected 2014 adjusted diluted EPS to a range from $3.60 to $3.85. -- Company expects 2014 reported diluted (GAAP) loss per share to be in the range from $1.35 to $1.10. -- Company announced the acquisitions of Grupo Farmaceutico Somar and Sumavel DosePro as it continues to transform into a leading global specialty healthcare company. -- Company entered into agreements to repurchase approximately $240 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2015. -- Company Reaches Agreements in Principle to Settle a Substantial Majority of AMS Litigation Cases.
Financial Release Dates -- Research on T-MobileUS, Endo Intl., Xcel Energy, and North American Palladium
PR Newswire - Thu May 01, 3:03AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: T-Mobile US Inc. (NYSE: TMUS), Endo International PLC (NASDAQ: ENDP), Xcel Energy Inc. (NYSE: XEL) and North American Palladium Ltd (NYSE MKT: PAL). Full earnings notes on TMUS, ENDP, XEL and PAL can be downloaded upon signing up at:
Stock Price Updates, Recognitions, Earnings Releases, and Acquisitions of Rights - Analyst Notes on HCA, Express Scripts, Tenet, Quest Diagnostics and Endo
PR Newswire - Thu May 01, 2:53AM CDT
Today, Analysts Review released its analysts' notes regarding HCA Holdings, Inc. (NYSE: HCA), Express Scripts Inc. (NASDAQ: ESRX), Tenet Healthcare Corp. (NYSE: THC), Quest Diagnostics Inc. (NYSE: DGX) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1814-100free.
Endo Health Solutions Inc. Announces Extension of Expiration Date and Reopening of Withdrawal Rights in Exchange Offers for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
PR Newswire Europe - Wed Apr 30, 5:44PM CDT
Endo International plc ("Endo" or the "Company"
announced today that its wholly-owned subsidiary, Endo Health Solutions Inc. ("EHSI" , has further extended the expiration date and reopened withdrawal rights in its previously announced offers to exchange any and all of the outstanding unsecured 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7A 1/4% Senior Notes due 2022 issued by EHSI (collectively, the "Existing EHSI Notes" , for new unsecured 7.00% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7.25% Senior Notes due 2022 (collectively, the "New Endo Finance Notes" , respectively, to be issued by Endo Finance LLC and Endo Finco Inc. (together, the "Endo Finance Issuers" and guaranteed by Endo Limited and certain of its direct and indirect subsidiaries. Capitalized terms used but not defined herein shall have the meanings ascribed to them in EHSI's Offer to Exchange dated March 27, 2014, as supplemented from time to time. Endo Reaches Agreements in Principle to Settle a Substantial Majority of AMS Litigation Cases
PR Newswire Europe - Wed Apr 30, 3:38PM CDT
Endo International plc today announced that it has reached agreements in principle with several leading plaintiffs' law firms, including Motley Rice LLC, Blasingame, Burch, Garrard & Ashley, P.C., Levin Simes LLP, and Clark, Love & Hutson, G.P., to resolve approximately 20,000 claims relating to vaginal mesh products sold by Endo's AMS subsidiary. The agreements, which are subject to final documentation, were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault. The settlements, once final, will resolve a substantial majority of the AMS vaginal mesh-related claims.
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
